Outside the box of immunotherapy - new hope for patients with advanced urothelial cancer

摘要

From the perspective of clinical oncology in general, immunotherapy has undoubtedly revolutionized the field. Whilst already making benefit of checkpoint inhibitors in routine clinical care, exemplified by three papers in the current issue [1-3], we are simultaneously in the midst of further exploring more effective immunotherapeutic strategies. For instance, intense research efforts are ongoing to better understand the mechanisms behind and to overcome de novo and acquired resistance to checkpoint inhibitors. Furthermore, development of novel effective regimens in the space of post-immunotherapy, highlighted below by the ongoing studies of Enfortumab Vedotin (EV) in advanced urothelial cancer (UC), is of great importance to keep improving quality of life and outcomes of our cancer patients.